scroll
LEARN MORE
Buy Hold Sell: The best and worst performers of FY25
Close
Tuesday 24th June – Dow up +374pts, SPI up +62pts
Close
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
TLX $24.40
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
| SHARE PRICE ACTIVITY | |
|---|---|
| Last (Price) | 24.40 |
| Change | -0.08 (-0.33) |
| Bid / Ask | 24.38 - 24.40 |
| Volume | 681,755 |
| Turnover | 16,626,965 |
| Open | 24.63 |
| Day Range | 24.07 - 24.69 |
| VWAP | 24.39 |
| Prev Close | 24.48 |
| Last Trade | 24/06 3:12pm (AEST) |
i
| KEY INFORMATION | |
|---|---|
| Sector | Healthcare |
| Shares Issued | 196,012,086 |
| NTA/Share | 0.00 |
| Last Dividend | 0.00 |
| Dividend Ex Date | 0 |
| Dividend Pay Date | 0 |
i
| CURRENT () | |
|---|---|
| Revenue | 783.21 |
| EBITDA | 99.28 |
| Profit | 49.92 |
| Earnings Per Share (EPS) | 0 |
| Dividend Per Share (DPS) | 0 |
| Yield % | 0.00 |
| Market Cap | 0 |
| Price to Earnings Ratio (P/E) | 169.29 |
i
TARGET PRICE FORECAST
i
| ESTIMATES () | |
|---|---|
| Revenue | 1,276.06 |
| EBITDA | 197.60 |
| Profit | 185.81 |
| Earnings Per Share (EPS) | 0.54 |
| Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
33.84
Lt Growth Rate
0.00
Recommendation (BUY)
1.77
Business Summary
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.
Relevant suggested news and content from the site
Video
WATCH
Buy Hold Sell: The best and worst performers of FY25
James Gerrish & Henry Jennings
Podcast
LISTEN
Tuesday 24th June – Dow up +374pts, SPI up +62pts
Daily Podcast Direct from the Desk
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here
